# Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy

> **NCT03244657** · PHASE4 · UNKNOWN · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Polypoid Choroidal Vasculopathy (PCV)

## Interventions

- **DRUG:** conbercept ophthalmic injection （0.5mg）
- **DRUG:** conbercept ophthalmic injection （0.5mg）

## Key facts

- **NCT ID:** NCT03244657
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-25
- **Primary completion:** 2019-10-31
- **Final completion:** 2020-02-28
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03244657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03244657, "Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03244657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*